Related Experiment Video
Updated: May 11, 2026
04:09
The Pocket-Creation Procedure of Endoscopic Submucosal Dissection for Large Rectal Laterally Spreading Tumors
Published on: February 13, 2026
[Solitary rectal ulcer syndrome].
Dariusz Waniczek1, Nina Rubicz, Marek Rudzki
1Katedra i Oddział Kliniczny Chirurgii Ogólnej i Gastroenterologicznej, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu, Slaski Uniwersytet Medyczny w Katowicach.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|May 10, 2013
Summary
Solitary rectal ulcer syndrome (SRUS) is a chronic rectal disease often linked to defecation issues. Treatment is challenging, with outcomes varying based on individual symptoms and rectal prolapse presence.
Area of Science:
- Gastroenterology
- Colorectal Surgery
- Pathology
Context:
- Solitary rectal ulcer syndrome (SRUS) is a complex benign rectal condition.
- Diagnosis relies on histopathologic criteria revealing specific glandular and architectural changes.
- Pathogenesis is incompletely understood, though linked to defecation disorders.
Purpose:
- To outline the characteristics, diagnostic criteria, and management challenges of Solitary Rectal Ulcer Syndrome.
- To emphasize the nonspecific nature of symptoms and the difficulties in achieving effective treatment.
- To highlight the impact of co-existing rectal prolapse on therapeutic options and prognosis.
Summary:
- SRUS presents with varied symptoms including incomplete defecation, rectal bleeding, and mucus discharge.
- Microscopic findings include edema, glandular alterations, and muscle penetration into the lamina propria.
- Treatment is often prolonged, with variable and frequently temporary results, necessitating individualized approaches.
Impact:
- SRUS management requires a tailored strategy considering symptom severity and potential rectal prolapse.
- The lack of a definitive treatment and unpredictable prognosis underscore the need for further research.
- Understanding SRUS, especially when associated with rectal prolapse, can improve patient outcomes.
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications
Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
01:24Peptic Ulcer Disease II: Pathophysiology
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
01:28Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...